focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Cold chain doubts delay COVID-19 vaccinations in some German cities

Sun, 27th Dec 2020 15:38

(Adds comments from district, BioNtech, Pfizer)

By Arno Schuetze

FRANKFURT, Dec 27 (Reuters) - Germany's coronavirus
vaccination campaign faced delays in several cities on Sunday
after temperature trackers showed that about 1,000 of the shots
made by BioNTech and Pfizer may not have been
kept cold enough during transit.

"When reading the temperature loggers that were enclosed in
the cool boxes, doubts arose about the compliance with the cold
chain requirements," the district of Lichtenfels in the north of
Germany's largest state, Bavaria, said in a statement.

Medical staff found that the temperature in one vaccine
transport cool box had risen to 15 degrees Celsius, a spokesman
for Lichtenfels said, above the maximum of 8C stipulated by the
manufacturers. He added that his district had not received
advice from BioNtech yet on how to proceed.

"We are looking into the case and are in contact with the
relevant districts," a BioNTech spokeswoman said, adding that
while BioNtech provides advice, it was up to the German
authorities to decide how to proceed.

In a December presentation, BioNtech had said that once
removed from the freezer, the vaccine can be stored for up to
five days at 2-8C and up to two hours at temperatures up to 30C,
prior to use.

Pfizer said that BioNtech was responsible for the shipment
to the 25 German distribution centres and that the federal
states and local authorities were responsible for the shipment
to the vaccination centres and the mobile vaccination teams.

"This is where the variations in temperature occurred. We
are in contact with many authorities to provide advice, however
it is up to them how to proceed", a Pfizer spokesperson said.

The vaccine, which uses new so-called mRNA technology, must
be stored at ultra-low temperatures of about -70 degrees Celsius
(-112°F) before being shipped to distribution centres in
specially designed cool boxes filled with dry ice.

Once out of ultra-low temperature storage, the vaccine must
be kept at 2C to 8C to remain effective for up to five days. The
cool boxes designed by Pfizer are fitted with GPS trackers so
the companies can deal with potential storage issues en route.

The spokesman for Lichtenfels said 1,000 shots had been
affected by the temperature issue and that the city and the
districts of Coburg, Kronach, Kulmbach, Hof, Bayreuth and
Wunsiedel in northern Bavaria were waiting to hear from BioNTech
about whether the vaccine could still be used.

"Vaccination against the coronavirus is not about who
vaccinates the fastest or who does the most doses. Safety and
conscientious work for the benefit of the population have the
highest priority," said Oliver Baer, district administrator in
Hof.

The European Union launched a mass COVID-19 vaccination
drive on Sunday with pensioners and medics lining up to get the
first shots to see off a pandemic that has crippled economies
and claimed more than 1.7 million lives worldwide.

The delays in Germany highlight the challenge in rolling out
the vaccine while regulators review for approval other shots,
including those made by Moderna and AstraZeneca,
which are easier to transport and store.

The roll-out of the Pfizer vaccine in the United States has
been slow putting the government's target of 20 million
vaccinations this month in doubt, as hospitals have navigated
preparing the previously frozen shots for use, finding staff to
run clinics and ensuring proper social distancing.

In Germany, similar temperature issues also delayed the
start of the vaccination campaign in the southern Bavarian
districts of Augsburg and Dillingen, where staff eventually got
clearance from BioNTech to use the shots.

Germany's vaccination campaign officially kicked off on
Sunday with residents of elderly care homes being inoculated.
The federal government is planning to distribute more than 1.3
million doses to local health authorities by the end of this
year and about 700,000 per week from January.
(Additional reporting by Josephine Mason; Editing by David
Clarke and Nick Macfie)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.